Clinical trial
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive…
NCT00385580 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00385580 |
|---|---|
| Title | Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer |
| Official title | Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | dasatinib |
| Enrollment | 94 |
| Start date | Jan 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Oct 1, 2010 |
| First posted | Oct 9, 2006 |
| Last update posted | Apr 30, 2013 |
| Countries | France, Italy, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: